<?xml version='1.0' encoding='utf-8'?>
<document id="20512579"><sentence text="Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model." /><sentence text="Everolimus (RAD001, Afinitor) is an mTORC1 pathway inhibitor, and vatalanib (PTK/ZK) is a pan VEGF-R tyrosine kinase inhibitor (TKI)"><entity charOffset="66-75" id="DDI-PubMed.20512579.s2.e0" text="vatalanib" /><entity charOffset="101-109" id="DDI-PubMed.20512579.s2.e1" text="tyrosine" /><pair ddi="false" e1="DDI-PubMed.20512579.s2.e0" e2="DDI-PubMed.20512579.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20512579.s2.e0" e2="DDI-PubMed.20512579.s2.e1" /></sentence><sentence text=" These two drugs have been shown to have overlapping but also distinct anti-angiogenic effects" /><sentence text=" Consequently, we investigated the pharmacokinetics (PK) and pharmacodynamics (PD) of their combination in vivo" /><sentence text="" /><sentence text="Murine melanoma B16/BL6 cells were grown orthotopically in BL6/C57 mice by injection into the derma of both ears to create a primary tumour which metastasized rapidly to the cervical lymph nodes" /><sentence text=" Mice were treated daily p" /><sentence text="o" /><sentence text=" with PTK/ZK (100 mg/kg) or everolimus (1 mg/kg) or their combination, and anti-tumour efficacy (PD) assessed"><entity charOffset="28-38" id="DDI-PubMed.20512579.s9.e0" text="everolimus" /></sentence><sentence text=" In the same model, plasma PK of everolimus was measured following single doses of the monotherapy or combination schedules"><entity charOffset="33-43" id="DDI-PubMed.20512579.s10.e0" text="everolimus" /></sentence><sentence text="" /><sentence text="Two independent experiments showed that combination of everolimus and PTK/ZK caused at least additive increases in anti-tumour activity compared to either monotherapy, without increases in toxicity"><entity charOffset="55-65" id="DDI-PubMed.20512579.s12.e0" text="everolimus" /></sentence><sentence text=" Pooling the data to improve the statistical power demonstrated the interactions to be synergistic" /><sentence text=" PK modelling showed that although PTK/ZK increased everolimus plasma concentrations by about twofold, this PK drug-drug interaction could not account for the increased anti-tumour effect of the combination"><entity charOffset="52-62" id="DDI-PubMed.20512579.s14.e0" text="everolimus" /></sentence><sentence text=" Modelling of the PTK/ZK dose-response curve in this model suggested that any effect of everolimus on the PK of PTK/ZK was unlikely to affect efficacy"><entity charOffset="88-98" id="DDI-PubMed.20512579.s15.e0" text="everolimus" /></sentence><sentence text=" Measurement of changes in tumour and plasma VEGF levels at the endpoint of therapy confirmed earlier observations of differential effects of these two agents" /><sentence text="" /><sentence text="The combination of everolimus and PTK/ZK hold promise for the treatment of human cancers"><entity charOffset="19-29" id="DDI-PubMed.20512579.s18.e0" text="everolimus" /></sentence><sentence text="" /></document>